Ipamorelin Dosage Chart
Solo and combined-with-CJC-1295 protocols, reconstitution math, and the timing windows that align with natural GH pulses.
Educational tool — not medical advice. This calculator provides estimates based on population averages and published trial data. Outputs are not clinical recommendations and do not replace evaluation by a qualified prescriber. Do not start, stop, or change a peptide therapy based on the result of this tool.
Ipamorelin is a selective growth-hormone secretagogue acting on the ghrelin receptor. It is widely considered the cleanest of the GH-releasing peptides because — unlike GHRP-2, GHRP-6, and hexarelin — it does not significantly elevate cortisol or prolactin at typical doses. It is most commonly paired with CJC-1295 (no DAC) to produce a synergistic, pulsatile GH release.
Ipamorelin at a Glance
| Solo dose | 200–300 mcg subQ, 1–3× per day |
|---|---|
| With CJC-1295 (no DAC) | 100–200 mcg of each, 1–3× per day |
| Best timing | Pre-bed (after fasting 90+ min) and/or fasted morning |
| Cycle length | 8–12 weeks on, 4 weeks off |
| FDA status | Not FDA-approved. Compounded; small human PK studies but no FDA dose-ranging trials. |
| Selectivity | Does not significantly elevate cortisol or prolactin (unlike GHRP-2/6, hexarelin) |
| Common vial size | 5 mg lyophilized powder |
Ipamorelin Reconstitution Chart
How vial size, bacteriostatic water volume, and insulin-syringe units convert for Ipamorelin. Use this to translate a prescribed mcg or mg dose into a syringe measurement.
| Vial size | Bac water | Concentration | Dose → insulin-syringe units (U-100) |
|---|---|---|---|
| 5 mg | 2 mL | 2.5 mg/mL (250 mcg per 0.1 mL) |
|
| 5 mg | 2.5 mL | 2 mg/mL (200 mcg per 0.1 mL) |
|
| 5 mg | 5 mL | 1 mg/mL (100 mcg per 0.1 mL) |
|
U-100 syringe reference: 100 units = 1.0 mL. So 10 units = 0.1 mL, 25 units = 0.25 mL, 50 units = 0.5 mL. If you receive a pre-mixed CJC/Ipa blend vial, the printed strength reflects the combined peptide load — confirm the per-component breakdown with your pharmacy.
Ipamorelin Dosing by Use Case
Commonly cited protocols vary by what Ipamorelin is being used for. The table below summarizes typical ranges reported in clinical practice and published literature.
| Use case | Typical dose | Frequency | Cycle length | Notes |
|---|---|---|---|---|
| Sleep / recovery (solo, single daily dose) | 200–300 mcg | Pre-bed, 90+ min after last meal | 8–12 weeks | Default single-dose protocol. Most accessible entry-level use. |
| Lean mass / body composition (with CJC-1295 no-DAC) | 100–200 mcg of each peptide | 1–3× daily (AM fasted, post-workout, pre-bed) | 8–12 weeks | Combined CJC/Ipa is the dominant body-composition protocol. |
| Anti-aging / general wellness | 200 mcg | Pre-bed, 5–7 nights per week | 12+ weeks with cycle breaks | Conservative protocol focused on overnight GH pulse alignment. |
Stacking Ipamorelin
Ipamorelin is most commonly stacked with CJC-1295 (no DAC) — the pairing is the dominant GH-secretagogue protocol in 2026 peptide therapy. Some practitioners also pair ipamorelin with tesamorelin (a GHRH analog with FDA approval) for visceral fat reduction in older patients.
Ipamorelin has the cleanest side-effect profile among GH secretagogues, but long-term human safety data is limited.
- •Common reported side effects: injection-site reactions, mild head-rush after injection, transient hunger increase (ghrelin-receptor mediated).
- •Does not significantly elevate cortisol or prolactin at typical doses, which is its main advantage over GHRP-2, GHRP-6, and hexarelin.
- •Theoretical concern with chronic GH elevation: insulin resistance, fluid retention, possible facilitation of cancer growth in patients with malignancy.
- •Long-term safety data in humans is limited to small studies. Most commercial development was discontinued.
- •Active or recent malignancy
- •Untreated hyperglycemia or poorly controlled diabetes
- •Pregnancy or breastfeeding
- •Children or adolescents outside specialist GH-deficiency care
Ipamorelin Dosing FAQ
The most common protocols are once daily (pre-bed only) or three times daily (AM fasted, post-workout, pre-bed). Once-daily is sufficient for sleep and recovery goals; multi-dose schedules are used when body composition is the primary goal and the patient can manage the compliance burden.
Combined dosing produces a larger GH pulse than either alone because the two peptides act on different receptors (ghrelin and GHRH respectively). For body composition or anti-aging goals, combined dosing is the standard. Solo ipamorelin is reasonable for patients prioritizing sleep alone or who are sensitive to additional peptides.
Elevated insulin from a recent meal blunts GH release. Most protocols specify at least 90 minutes after the last meal, and longer (2–3 hours) for pre-bed dosing, to maximize the GH pulse triggered by the peptide.
Ipamorelin is not on the WADA Prohibited List by name, but GH-releasing peptides as a class are prohibited in competitive sport. WADA's S2 category covers peptide hormones and growth factors broadly. If you compete under WADA-aligned testing, do not use ipamorelin.
Sources
Related Dosage Charts
Want the full Ipamorelin guide?
Mechanism, clinical evidence, side effects, costs, and provider listings for Ipamorelin therapy.
See Ipamorelin guideMedical Disclaimer: This content is for informational purposes only and should not be considered medical advice. Always consult with a qualified healthcare provider before beginning any peptide therapy treatment.